We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Combined Pharmaceutical Freeze Drying Service Blends German and Chinese Expertise

By LabMedica International staff writers
Posted on 20 Aug 2012
In November 2010, GEA Pharma Systems (Hürth, Germany) acquired Beijing Sino-German Tianhe Technology (BSGT; Beijing, China) to create GEA Lyophil (Beijing), Ltd. More...
Since then, the company has quadrupled turnover and enhanced its customer service by integrating German quality and Chinese economy to provide a unique combined offering to its pharmaceutical clients.

Jinbin Tang, MD, GEA Lyophil, Ltd. (Beijing) reported that the market had changed in China since the introduction of new requirements for good manufacturing practice (GMP) production. This had increased the requirement for high quality pharmaceutical freeze drying lines, especially in combination with ALUS (automatic load and unload systems), a technology in which GEA Lyophil in Germany are a recognized world authority. “The key for us is to make sure we use the facilities and talents of the Chinese and German manufacturing centers fully,” he explained. “We have made freeze drying machines in China for many years however it is GEA Lyophil, Germany that is the true master of ALUS. By combining both technologies, we have the ability to provide our customers with complete, cost-effective GMP production lines with the quality and security of outcome that would be expected from a German manufacturer.”

Heinrich Meintrup, managing director of GEA Lyophil in Germany, concurred: “Having this combined option allows us to blend the benefits of German quality with a more cost-effective approach. We have never been willing to play the ‘low cost’ game, it just doesn’t work, but this quality/price performance model makes our offering unique.”

The key markets for GEA Lyophil in China come from the pharmaceutical companies who acknowledge that they need to use recognized, top-quality equipment to compete on their local market as well as on a world export stage. “Most of our customers are making anticancer drugs, antibiotics or expensive biological products where top quality, security of outcome, and reliable containment are essential,” said Dr. Tang. “They consider our lines to represent the image of their companies.”

This approach has allowed GEA Lyophil to expand its customer base to include the top-end customers that require leading technology and also provide the economy needed for those that do not have such crucial requirements. Although China is beginning to suffer from less rapid growth than in recent years, both Dr. Tang and Mr. Meintrup are optimistic about the outlook in China. “We expect another big jump this and next year because of the new GMP regulations,” said Dr. Tang. “Beyond that we still expect above average growth from the pharmaceutical sector.”

One product that is becoming very popular in China, according to Dr. Tang, is the GEA Lyophil range of cost-effective pharmaceutical freeze dryers called Smart LYO. The systems are based on modular units that have been made using validated technology with comprehensive manufacturing skills and techniques. This keeps the costs down without compromising quality, performance, or system architecture/flexibility; makes validation and documentation easier; and reduces delivery times.

Related Links:

GEA Pharma Systems



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.